These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2708138)

  • 21. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I).
    Periti P; Mazzei T; Mini E; Novelli A
    Clin Pharmacokinet; 1989 Apr; 16(4):193-214. PubMed ID: 2656049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Further microbiological investigations of flurithromycin against gram-positive bacteria and mycoplasmas.
    Furneri P; Nicoletti G; Russo G; Stefani S; Tempera G
    Chemioterapia; 1987 Jun; 6(2 Suppl):161-3. PubMed ID: 3509378
    [No Abstract]   [Full Text] [Related]  

  • 23. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
    Mazzariol A; Koncan R; Vitali LA; Cornaglia G
    J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial susceptibility and susceptibility testing of Mycoplasma hominis: a review.
    Bygdeman SM; Mårdh PA
    Sex Transm Dis; 1983; 10(4 Suppl):366-70. PubMed ID: 6364407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The in-vitro activity of clarithromycin and other macrolides against the type strain of Chlamydia pneumoniae (TWAR).
    Ridgway GL; Mumtaz G; Fenelon L
    J Antimicrob Chemother; 1991 Feb; 27 Suppl A():43-5. PubMed ID: 1827101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibacterial profile of flurithromycin, a new macrolide.
    Saverino D; Debbia EA; Pesce A; Lepore AM; Schito GC
    J Antimicrob Chemother; 1992 Sep; 30(3):261-72. PubMed ID: 1452490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Semi-synthetic derivatives of erythromycin.
    Kirst HA
    Prog Med Chem; 1993; 30():57-88. PubMed ID: 8303037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of flurithromycin, a novel macrolide antibiotic.
    Gialdroni Grassi G; Alesina R; Bersani C; Ferrara A; Fietta A; Peona V
    Chemioterapia; 1986 Jun; 5(3):177-84. PubMed ID: 3487389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roxithromycin alone and in combination with sulphamethoxazole against Haemophilus influenzae.
    Lapointe JR; Lavallée C; Meilleur R; Bourget C
    J Antimicrob Chemother; 1987 Nov; 20 Suppl B():21-9. PubMed ID: 3501425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The comparative in vitro activity of spiramycin and erythromycin against Norwegian bacterial isolates.
    Dibb WL; Ragnhildstveit E
    NIPH Ann; 1986 Dec; 9(2):61-3. PubMed ID: 3101004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-activity relationships for three macrolide antibiotics in Haemophilus influenzae.
    Mabe S; Eller J; Champney WS
    Curr Microbiol; 2004 Oct; 49(4):248-54. PubMed ID: 15386112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased activity of 16-membered lactone ring macrolides against erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae: characterization of South African isolates.
    Klugman KP; Capper T; Widdowson CA; Koornhof HJ; Moser W
    J Antimicrob Chemother; 1998 Dec; 42(6):729-34. PubMed ID: 10052895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection.
    Vallée E; Azoulay-Dupuis E; Swanson R; Bergogne-Bérézin E; Pocidalo JJ
    J Antimicrob Chemother; 1991 Feb; 27 Suppl A():31-41. PubMed ID: 1827100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-vitro comparison of roxithromycin and erythromycin against 900 anaerobic bacterial strains.
    Dubreuil L
    J Antimicrob Chemother; 1987 Nov; 20 Suppl B():13-9. PubMed ID: 3429381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of three 4"-deoxy-4"-sulfonamido-oleandomycin derivatives with erythromycin-like antibacterial potency.
    English AR; Retsema JA; Girard AE; Schelkly W; Lynch JE
    Antimicrob Agents Chemother; 1984 Jan; 25(1):118-22. PubMed ID: 6703675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The in vitro activity of roxithromycin (RU 28965) compared with four oral antibiotics.
    Drabu YJ; Mehtar S; Blakemore PH
    Drugs Exp Clin Res; 1987; 13(4):201-3. PubMed ID: 3622250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Josamycin: interpretation of inhibition zones with the Bauer-Kirby agar disk diffusion test as compared with erythromycin.
    Karthein J; Spohr M; Traub WH
    Chemotherapy; 1986; 32(4):336-43. PubMed ID: 3731919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraphagocytic activity of erythromycin, roxithromycin and azithromycin.
    Milatovic D
    Eur J Clin Microbiol Infect Dis; 1990 Jan; 9(1):33-5. PubMed ID: 2154381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of roxithromycin against respiratory pathogens.
    Facinelli B; Varaldo PE
    J Chemother; 1991 Jan; 3 Suppl 1():33-5. PubMed ID: 12041781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The in-vitro activity of pristinamycin against Haemophilus influenzae and Neisseria meningitidis.
    Lafaix C; Bouvet E; Dublanchet A; Dabernat H; Carrere C; Picq JJ; Etienne J
    J Antimicrob Chemother; 1985 Jul; 16 Suppl A():221-3. PubMed ID: 3932307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.